Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma

Immune checkpoint blockade has altered the treatment landscape for many cancers. In the first wave of immunotherapy approvals, studies showed that patients with highly immunogenic tumours such as malignant melanoma gained substantial survival benefits from treatment with anti-CTLA-4 or anti-PD-1 antibodies.1,2 These early wins have given way to mixed evidence for immunotherapy for tumours on the margin of immune exclusion, such as gastro-oesophageal adenocarcinoma. Anti-PD-1 therapy has been shown to be associated with modest response rates and an improvement in overall survival in chemorefractory gastro-oesophageal cancer.